Design and synthesis of anti-HCV drug sofosbuvir:research advances / 国际药学研究杂志
Journal of International Pharmaceutical Research
; (6): 918-924, 2017.
Article
em Zh
| WPRIM
| ID: wpr-693337
Biblioteca responsável:
WPRO
ABSTRACT
Sofosbuvir is a new type of direct-acting antiviral(DAA)drugs against hepatitis C.By competitive combination to NS5B polymerase activity sites,sofosbuvir can terminate genome synthesis of newly born virus,and finally inhibit the replication of hepatitis C virus(HCV).The research and development process of sofosbuvir is based on the principles of nucleoside antiviral drug metabolism.The subtle structure modification improves the drug′s structure stability and absorption process,which makes sofosbuvir a liver targeted anti-HCV drug.Sofosbuvir has become a clinical fundamental drug for anti-HCV infection,and then used alone or in combination with other drugs,with higher recovery rate,better safety and anti-drug resistance.This article reviews the research back?ground,development process,clinical application and synthetic methods for sofosbuvir.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of International Pharmaceutical Research
Ano de publicação:
2017
Tipo de documento:
Article